• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Feb. 16, 2018

View Archived Issues

In the clinic

Eisai Inc., of Woodcliff Lake, N.J., the U.S. subsidiary of Tokyo-based Eisai Co. Ltd., said data from the phase III REFLECT trial testing Lenvima (lenvatinib mesylate) in 954 patients with unresectable hepatocellular carcinoma were published in The Lancet. Lenvima produced a median overall survival of 13.6 months compared to 12.3 months for Nexavar (sorafenib, Bayer AG). Read More

Earnings

Acorda Therapeutics Inc., of Ardsley, N.Y., reported Ampyra (dalfampridine) extended-release tablets, 10 mg, indicated to help improve walking in adults with multiple sclerosis (MS), achieved net revenue of $167.2 million for the quarter ending Dec. 31, 2017, compared to $132.3 million for the same quarter in 2016. Read More

Appointments and advancements

Immunocore Ltd., of Oxford, U.K., appointed Andrew Hotchkiss, who is chief commercial officer, interim CEO. Read More

Financings

Active Biotech AB, of Lund, Sweden, said it is planning a rights issue of approximately SEK48 million (US$6 million). When implemented, existing shareholders will be entitled to subscribe for the new shares with preemptive rights, with two existing shares entitling a holder to subscribe for one new share at SEK1 per share. Read More

Holiday notice

BioWorld's offices will be closed in observance of Presidents Day in the U.S. Read More

Sorrento, Yuhan JV set to open trials of anti-PD-L1 antibody in South Korea

HONG KONG – The IND filed by Immuneoncia Therapeutics Inc. for its anti-PD-L1 candidate received a speedy approval from the South Korean Ministry of Food and Drug Safety (MFDS), setting the stage for initiation of clinical trials. Read More

Australia's NME approvals fall to five-year low in 2017

PERTH, Australia – In 2017, Australia's Therapeutic Goods Administration (TGA) approved the lowest number of new molecular entities since 2012 – just 34, compared to 42 in 2016 and 45 in 2015. Read More

FDA pilot delivers payload to guide development of neurological drugs

FDA experts are teaming up with patients to help drug developers explore one of the final frontiers in the human body as they seek new cures and therapies for neurological diseases. Read More

Trihep's bulging in regard of Ultragenyx speculators; add-on to Mepsevii muscle

At the WORLD Symposium on lysosomal diseases in San Diego this month, Ultragenyx Pharmaceutical Inc. made a splash with data related to Mepsevii (vestronidase alfa-vjbk, previously UX-003), the company's first drug to win approval. Read More

Other news to note

Tosk Inc., of Mountain View, Calif., said it received a two-year, $2 million phase II Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI) to support its kRAS oncogene drug R&D program. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 6, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 6, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Gilead Sciences divulges new compounds to treat herpes virus infection

    BioWorld Science
    Gilead Sciences Inc. has synthesized indoline compounds acting as DNA helicase-primase complex (human herpes simplex virus) and viral replication inhibitors...
  • Biotech deal illustration

    City hits the town with $1B-plus deal with Biogen

    BioWorld
    A development deal with Biogen Inc. could eventually bring City Therapeutics Inc. about $1 billion in milestone payments. It’s a step in the direction the company...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe